Want to join the conversation?
Pharma major $AGN said it filed a de novo application with the Food and Drug Administration (FDA) for the Oculeve Intranasal Tear Neurostimulator device, which increases tear production upon activation in patients with dry eye disease. De novo application is an alternate pathway to classify novel devices of low to moderate risk.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th